Structural and functional characterization of B-domain deleted recombinant factor VIII.

abstract：:The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：1999-10-01 00:00:00

abstract：:The value of prophylaxis against venous thromboembolism (VTE) is increasingly accepted in most surgical specialties, although the potential reduction in fatal pulmonary embolism has recently been questioned. The burden of VTE in hospital patients nevertheless remains high, partly attributable to underuse of thrombopro...

journal_title：Seminars in hematology

authors： Wille-Jørgensen P

更新日期：2001-04-01 00:00:00

abstract：:The introduction of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL) has dramatically altered the landscape of treatment options available to children and adults with ALL. With complete remission induction rates exceeding 70% in most trials and FDA approval of one CD19 CAR T-cell co...

journal_title：Seminars in hematology

authors： Marple AH,Bonifant CL,Shah NN

更新日期：2020-07-01 00:00:00

abstract：:CD59 and decay-accelerating factor (DAF) are glycosylphosphatidylinositol (GPI)-anchored complement regulatory proteins critical for regulating complement activation on the host cell surface. Defective expressions of CD59 or DAF caused by mutations in the genes coding for these proteins or genes involved in the biosyn...

journal_title：Seminars in hematology

authors： Kinoshita T

更新日期：2018-07-01 00:00:00

abstract：:The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

journal_title：Seminars in hematology

authors： George JN,Vesely SK,Terrell DR

更新日期：2004-01-01 00:00:00

abstract：:There is consensus that human herpesvirus 8 (HHV-8) is a necessary, albeit not sufficient, causal agent of Kaposi's sarcoma (KS). In the past several years, there have been rapid advances in our understanding of HHV-8 infection. In diagnosis, antibody detection is more sensitive than nucleic acid-based techniques. Whi...

journal_title：Seminars in hematology

authors： Martin JN

更新日期：2003-04-01 00:00:00

abstract：:During myeloid differentiation, the pluripotent hematopoietic stem cell passes through several well-defined morphologic stages within the bone marrow. These changes include progressive nuclear segmentation and the acquisition of stage-specific granules. Primary granules appear at the myeloblast stage, and are found in...

journal_title：Seminars in hematology

authors： Sigurdsson F,Khanna-Gupta A,Lawson N,Berliner N

更新日期：1997-10-01 00:00:00

abstract：:Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

journal_title：Seminars in hematology

authors： Bonadonna G,Santoro A,Viviani S,Valagussa P

更新日期：1988-04-01 00:00:00

abstract：:Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patie...

journal_title：Seminars in hematology

authors： Beutel G,Ganser A

更新日期：2007-07-01 00:00:00

abstract：:Von Willebrand disease (VWD) is the most commonly inherited bleeding disorder, caused by inheritance of a quantitative or qualitative abnormality of von Willebrand factor (VWF). While the majority of patients with VWD are successfully treated with adjunctive therapies or with the synthetic vasopressin analog desmopres...

journal_title：Seminars in hematology

authors： Hambleton J

更新日期：2001-10-01 00:00:00

abstract：:Activation products of the terminal complement cascade potently affect granulocyte function, inducing, for example, their migration toward (chemotaxis), and adherence to (opsonization), microbes, and stimulating their production of microbicidal oxygen radicals such as superoxide anion, and the like. We present studies...

journal_title：Seminars in hematology

authors： Craddock PR,Hammerschmidt DE,Moldow CF,Yamada O,Jacob HS

更新日期：1979-04-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was firs...

journal_title：Seminars in hematology

authors： Capdeville R,Silberman S

更新日期：2003-04-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal proliferation of myeloid progenitors leading to erythrocytosis, thrombocytosis, or leukocytosis, and risk of hemorrhagic and thrombotic events, as well as ...

journal_title：Seminars in hematology

authors： Ferreira Cristina S,Polo B,Lacerda JF

更新日期：2018-10-01 00:00:00

abstract：:Idiopathic thrombocytopenic purpura (ITP) is an illness of primary acquired thrombocytopenia occurring in the absence of marrow failure. Splenectomy was first used as a treatment for ITP in 1913. However, with the realization that opsonin (critical for the optimal killing of invasive micro-organisms by white blood cel...

journal_title：Seminars in hematology

authors： Bell WR Jr

更新日期：2000-01-01 00:00:00

abstract：:Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease af...

journal_title：Seminars in hematology

authors： Connors JM,Klimo P

更新日期：1987-04-01 00:00:00

abstract：:Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

journal_title：Seminars in hematology

authors： Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

更新日期：2010-07-01 00:00:00

abstract：:TET2 is one of the most frequently mutated genes in myeloid neoplasms. TET2 loss-of-function perturbs myeloid differentiation and causes clonal expansion. Despite extensive knowledge regarding biochemical mechanisms underlying distorted myeloid differentiation, targeted therapies are lagging. Here we review known bioc...

journal_title：Seminars in hematology

authors： Guan Y,Hasipek M,Tiwari AD,Maciejewski JP,Jha BK

更新日期：2021-01-01 00:00:00

abstract：:Peripheral suppression of autoreactive T cells by specialized T-cell populations is one of several mechanisms ensuring self-tolerance within the adaptive immune system. Thymus-derived CD4+CD25+ T cells expressing the transcriptional repressor FOXP3 mediate such immunoregulatory functions and are pivotal for the preven...

journal_title：Seminars in hematology

authors： Hoffmann P,Edinger M

更新日期：2006-01-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a complex and heterogeneous disease with distinct age-associated genomic and epigenomic alterations. A large number of somatic karyotypic and molecular alterations have been identified in AML to date; however, very few predict outcome or identify potential therapeutic targets. Here we d...

journal_title：Seminars in hematology

authors： Schuback HL,Arceci RJ,Meshinchi S

更新日期：2013-10-01 00:00:00

abstract：:A retrospective study was conducted to determine treatment patterns for idiopathic thrombocytopenia purpura (ITP) across the US and to determine the cost of its treatment with high-dose intravenous immunoglobulin (IVIg) and anti-D therapy. Information on the incidence, treatment patterns, hospital care, and costs for ...

journal_title：Seminars in hematology

authors： Simpson KN,Coughlin CM,Eron J,Bussel JB

更新日期：1998-01-01 00:00:00

abstract：:Despite the development of more effective therapies for multiple myeloma (MM) over the past decade, nearly all patients will eventually experience disease relapse and require further therapy. Designing the next generation of therapies for relapsed and refractory disease will depend on understanding the complex molecul...

journal_title：Seminars in hematology

authors： Siegel DS

更新日期：2012-07-01 00:00:00

abstract：:The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

journal_title：Seminars in hematology

authors： Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

更新日期：1988-04-01 00:00:00

abstract：:Large scale sequencing projects over the past 2 decades have led to the identification of many common genomic alterations in hematolymphoid neoplasms, some of which with diagnostic, therapeutic, and prognostic implications [1-3]. Although these alterations can be tested individually with high sensitivity and specifici...

journal_title：Seminars in hematology

authors： Kuo FC

更新日期：2019-01-01 00:00:00

abstract：:In previous studies, treatment with epoetin alfa facilitated preoperative donation of autologous blood (AB). However, some patients may not be able to donate sufficient AB to meet their surgical blood requirements when the time to surgery is short. In this multicenter, double-blind, placebo-controlled study, the abili...

journal_title：Seminars in hematology

authors： Tryba M

更新日期：1996-04-01 00:00:00

abstract：:Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than...

journal_title：Seminars in hematology

authors： Hedner U

更新日期：2001-10-01 00:00:00

abstract：:The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream...

journal_title：Seminars in hematology

authors： Tefferi A

更新日期：1999-01-01 00:00:00

abstract：:Stem cell transplantation is a recognized treatment for many hematologic malignancies. Human leukocyte antigen (HLA) testing is a key assessment in the evaluation of potential recipients and selection of the appropriate stem cell donor. Over the past several years, technological advances have moved HLA testing from a ...

journal_title：Seminars in hematology

authors： Bray RA

更新日期：2001-04-01 00:00:00

abstract：:Anemia is a common, multifactorial condition among older adults. The World Health Organization (WHO) definition of anemia (hemoglobin concentration <12 g/dL in women and <13 g/dL in men) is most often used in epidemiologic studies of older adults. More than 10% of community-dwelling adults age 65 years and older has W...

journal_title：Seminars in hematology

authors： Patel KV

更新日期：2008-10-01 00:00:00

abstract：:Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

journal_title：Seminars in hematology

authors： Ng HJ,Crowther MA

更新日期：2006-01-01 00:00:00

abstract：:Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

journal_title：Seminars in hematology

authors： Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

更新日期：2003-10-01 00:00:00